SCHEMBL23819641

SCHEMBL23819641

CC(C)(C(=O)N(O)Cc1cc(F)c(F)c(F)c1)C(F)(F)F

nearest known ligand 0.68

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
▸ RIPK1 Q13546 16/20 0.68
▸ MAOB P27338 1/20 0.33
▸ MEP1B Q16820 1/20 0.33
▸ CES2 O00748 1/20 0.32
▸ CES1 P23141 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17882184 0.91 RIPK1 (0.68) RIPK1MAOBMEP1BCES2CES1
SCHEMBL23803566 0.86 RIPK1 (0.50) RIPK1
SCHEMBL17874145 0.81 RIPK1 (1.00) RIPK1
SCHEMBL23803521 0.79 RIPK1 (0.68) RIPK1
SCHEMBL23803517 0.78 RIPK1 (0.64) RIPK1
SCHEMBL17882167 0.76 RIPK1 (0.70) RIPK1MAOBMEP1B
SCHEMBL23803571 0.75 RIPK1 (0.50) RIPK1MAOB
SCHEMBL23803531 0.75 RIPK1 (0.50) RIPK1
SCHEMBL17882281 0.72 RIPK1 (0.65) RIPK1MAOB
SCHEMBL17882185 0.72 RIPK1 (0.71) RIPK1CES2CES1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3883918-B1 RIP1 INHIBITORS SIRONAX LTD (KY) 2023-07-19 — — EP disclosed
US-20210284598-A1 RIP1 Inhibitors SIRONAX LTD (KY) 2021-09-16 — — US disclosed
CN-113272272-A RIP1 inhibitors 圣瑞诺有限公司 2021-08-17 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210284598-A1 RIP1 Inhibitors RIPK1, RIPK3, RIPK4 RIPK1 1/4885MAOB 4796/4885MEP1B 2137/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback